exclusive, exclusive, or partially exclusive: LigoCyte Pharmaceuticals, Inc.,
[Federal Register: April 25, 2002 (Volume 67, Number 80)]
[Notices]
[Page 20542]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr25ap02-78]
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive License: Synthetic Ordered Arrays of Antigen for the Induction of Autoantibodies
AGENCY: National Institutes of Health, Public Health Service, DHHS.
ACTION: Notice.
SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of an exclusive license to practice the invention embodied in United States Patent Application 09/835,124 and its foreign equivalents, entitled ``Virus-Like Particles for the Induction of Autoantibodies,'' filedon April 13, 2001, with priority back to U.S. S/N 60/105,132, filedOctober 21, 1998, to LigoCyte Pharmaceuticals, Inc., having a place of business in Bozeman, Montana. The patent rights in this invention have been assigned to the United States of America.
DATES: Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before June 24, 2002, will be considered.
ADDRESSES: Requests for a copy of the patent application, inquiries, comments and other materials relating to the contemplated license should be directed to: Peter Soukas, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852-3804; e-mail: ps193c@nih.gov; telephone: (301) 496- 7056, ext. 268; facsimile: (301) 402-0220.
SUPPLEMENTARY INFORMATION: This invention claims compositions and methods for producing antibodies to tolerogens (self-antigens normally exposed to B cells that fail to induce an antibody response). The compositions of the invention comprise multiple copies of a tolerogen (or at least one B cell epitope of a tolerogen) chimerized to capsomeric structures or capsid proteins in an orderly manner. This invention could potentially replace any treatment utilizing chronic administration of a monoclonal antibody that reacts with a self- antigen.
The prospective exclusive license will be royalty bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless, within 60 days from the date of this published Notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.
The field of use may be limited to non-Virus-Like Particle (VLP) polyvalent liposome nanoparticle vaccines against self-antigens.
Properly filedcompeting applications for a license filedin response to this notice will be treated as objections to the contemplated license. Comments and objections submitted in response to this notice will not be made available for public inspection, and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552.
Dated: April 17, 2002. Jack Spiegel, Director, Division of Technology Development and Transfer, Office of Technology Transfer.
[FR Doc. 02-10116Filed4-24-02; 8:45 am]
BILLING CODE 4140-01-P
